Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG with or without mitomycin for high-risk non-muscle invasive bladder cancer
ACTRN12613000513718Phase 3Completed
- Sponsor
- University of Sydney
- Start
- Dec 2013
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bcg vaccine and mitomycin c in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by University of Sydney. Primary endpoint: Disease-free survival. Started Dec 2013; status: completed.
02
Drugs
bcg vaccinemitomycin c
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ACTRN12613000513718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000513718.